27
May
2021
From Fitness To Flourish: Expanding the Scope of Digital Exercise
Sometimes the most relevant digital health companies have the least elaborate technology. More than a decade ago, I discussed UpToDate, a fairly basic medicine e-textbook, served through a web-based app. It was then, and still remains, a go-to site for timely, high-quality medical information relevant to clinicians. There’s nothing fancy about it, it just works. Recently, I discovered a similar... Read More
26
May
2021
11 Asian-American Executives Shaping the Future of Biopharma
The biopharma industry was pressured to get faster and more innovative to respond to the urgent global health challenge of the past year. Asian-American executives have played a key role in leading this charge, although they often aren’t in front of the cameras and microphones. As part of Asian American and Pacific Islander Heritage Month, we wanted to stop and... Read More
20
May
2021
GSK Persists with Vaccines, ASCO Abstracts, & Biogen Gene Therapy Fizzles
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
May
2021
SQZ Biotech Shortens Cell Therapy Manufacturing Time, Demonstrates Safety
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
May
2021
Vedere II, After Novartis Acquisition, Snags $77M for Gene Therapy to Restore Vision
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
May
2021
Singapore: Punching Above its Weight to Become BioNTech’s Regional mRNA Partner
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
May
2021
Learning From Post-It: Your Solution Is Not My Problem – Except When It is
A frequent – and frequently correct – critique of entrepreneurs bearing technology is “your solution is not my problem.” Healthcare – among many other domains, perhaps all domains – has been beset by “solutionism,” the idea that my clever technology will solve your hideously complex problem. But perhaps it makes no more sense to instinctively reject this mindset as it... Read More
13
May
2021
Pfizer Advances to Adolescents, Xontogeny’s New Fund & Rekindling Curiosity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
May
2021
Aducanumab & the Alzheimer’s Moonshot: What Would It Be Worth to Keep Your Mind?
Have you ever met someone with Alzheimer’s disease? Odds are you probably have. Odds are that question calls to mind the face of a beloved grandparent, neighbor, or family friend whom you’ve stopped by to visit, nervously clenching a bouquet of flowers. You greet them hopefully and wonder if they’ll remember you this time. America’s population is aging. About 6.2... Read More
11
May
2021
Appia Bio Seeks Off-the-Shelf Cancer Therapy With Rare iNKT Cells
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
May
2021
Biden Threatens Patents, Vaccines Shine, & Biogen’s Pricing Predicament
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
May
2021
Motivating Fitness With Immersive Experience, Rather Than Competition
Many of us first experience exercise as kids playing sports. Think back to the coach yelling at you and your teammates to run the extra lap. Maybe this helps explain why fitness and competition seem inextricably linked to so many adults, so many years later. Digital fitness companies know this. Many digital fitness offerings lean heavily into the competitive aspect,... Read More
5
May
2021
Startup Profiles: Perlmutter Bets on Super Microscopy; Foresite’s Precision Immunology
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
May
2021
Spotting Trends and Starting Edgy Companies: Daphne Zohar on The Long Run
Today’s guest on The Long Run is Daphne Zohar. Daphne is the founder and CEO of Boston-based Puretech Health. Puretech has been around since 2005, seeking to capitalize on some of the big trends in biotech. It started out seeking to test concepts from academic labs that could be the basis for new biotech companies – what’s now commonly called... Read More
3
May
2021
RT-PCR Tests for COVID-19 Have Quantitative Power. Let’s Start Using It
Over the past 16 months, 192 billion COVID tests have been carried out globally. A majority are real-time polymerase chain reaction tests (RTqPCR) tests. Every one of those has been reported to patients as an either/or result: positive or, more usually, negative. These tests are capable of doing much, much more than just giving a simple yes/no answer. The “q”... Read More
3
May
2021
Single Cell Analysis Comes of Age, Lighting the Way for Precision Therapies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Apr
2021
J&J Back After Pause, Sanofi Aids Moderna, and a Flood of Women Join Biotech Boards
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Apr
2021
AbbVie Bets $90M on Capsida Approach to AAV Gene Therapy
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Apr
2021
Rare Side Effects of Adenovirus Vaccines Call for Careful Surveillance
Clinical trials have given us a wealth of information about the effectiveness, and safety profile, of vaccines for COVID-19. But the work of gathering evidence, and weighing the results in the context of an ongoing pandemic, isn’t done. The importance of developing population-based effectiveness and safety profiles associated with a mass vaccination campaign — the sort of deep datasets that... Read More
28
Apr
2021
Boundless Bio, Pushing Frontiers with ecDNA Cancer Therapy, Raises $105M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.